Abstract
We describe the use of amrubicin hydrochloride to treat small cell carcinoma of the prostate in a 23-year-old man. Initial radiological examinations of the patient revealed a pelvic tumor associated with bilateral hydronephrosis, pelvic lymph node swelling, and lumbar vertebral bone metastases. The pathological diagnosis was small cell carcinoma originating in the prostate, based on positive immunohistochemical staining for neuron-specific enolase, synaptophysin, and myoglobulin; and negative staining for CD3e, CD20, leukocyte common antigen, and CD99. The clinical stage was T4N1M1. A bilateral nephrostomy was performed to improve renal function, and an ileostomy was established to prevent ileus. The first induction chemotherapy consisted of amrubicin 35 mg/m2 (days 1, 2, 3, monthly). The amrubicin regimen caused a dramatic reduction in tumor size, but could not be continued, because of the occurrence of grade 4 diarrhea. A different regimen was then administered, consisting of one cycle of a 50% dose and a second cycle of a 75% dose of etoposide (100 mg/m2 days 1, 2, 3), coadministered with carboplatin (AUC 5, plasma concentration curve). Five months after the induction of chemotherapy, the patient suffered respiratory arrest and died.
Similar content being viewed by others
References
Amato RJ, Logothetis CJ, Hallinan R, et al. (1992) Chemotherapy for small cell carcinoma of prostatic origin. J Urol 147:935–937
Trotz C (2003) Prostate cancer with a normal PSA: small cell carcinoma of the prostate—a rare entity. J Am Board Fam Pract 16:343–344
Uramoto H, Kagami S, Iwashige A, et al. (2006) Chemotherapy for lung cancer patients. J UOEH 28:75–84
Yashi M, Terauchi F, Nukui A, et al. (2006) Small-cell neuroendocrine carcinoma as a variant form of prostate cancer recurrence: a case report and short literature review. Urol Oncol 24:313–317
Turbat-Herrera EA, Herrera GA, Gore I, et al. (1988) Neuroendocrine differentiation in prostatic carcinomas. A retrospective autopsy study. Arch Pathol Lab Med 112:1100–1105
Moore SR, Reinberg Y, Zhang G (1992) Small cell carcinoma of prostate: effectiveness of hormonal versus chemotherapy. Urology 39:411–416
Asmis TR, Reaume MN, Dahrouge S, et al. (2006) Genitourinary small cell carcinoma: a retrospective review of treatment and survival patterns at The Ottawa Hospital Regional Cancer Center. BJU Int 97:711–715
Ogawa M (1999) Novel anticancer drugs in Japan. J Cancer Res Clin Oncol 125:134–140
Kurai J, Igishi T, Suyama H, et al. (2006) A case of small-cell lung cancer effectively treated by bi-weekly administration of amrubicin. Japanese Journal of Cancer and Chemotherapy 33:373–375
Sawa T, Yana T, Takada M, et al. (2006) Multicenter phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer (Study 1): West Japan Thoracic Oncology Group (WJTOG) trial. Invest New Drugs 24:151–158
Ikegami T, Ha L, Arimori K, et al. (2002) Intestinal alkalization as a possible preventive mechanism in irinotecan (CPT-11)-induced diarrhea. Cancer Res 62:179–187
Kandabashi K, Sasaki T (2006) Management of chemotherapy-induced mucositis and diarrhea. Japanese Journal of Cancer and Chemotherapy 33:24–28
Matsunaga Y, Hamada A, Okamoto I, et al. (2006) Pharmacokinetics of amrubicin and its active metabolite amrubicinol in lung cancer patients. Ther Drug Monit 28:76–82
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Katou, M., Soga, N., Onishi, T. et al. Small cell carcinoma of the prostate treated with amrubicin. Int J Clin Oncol 13, 169–172 (2008). https://doi.org/10.1007/s10147-007-0702-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-007-0702-x